Acumen Pharmaceuticals, Inc.

NasdaqGS:ABOS Stock Report

Market Cap: US$141.8m

Acumen Pharmaceuticals Management

Management criteria checks 2/4

Acumen Pharmaceuticals' CEO is Dan O'Connell, appointed in Dec 2014, has a tenure of 9.92 years. total yearly compensation is $3.93M, comprised of 15.2% salary and 84.8% bonuses, including company stock and options. directly owns 0.042% of the company’s shares, worth $60.15K. The average tenure of the management team and the board of directors is 3 years and 6.1 years respectively.

Key information

Dan O'Connell

Chief executive officer

US$3.9m

Total compensation

CEO salary percentage15.2%
CEO tenure9.9yrs
CEO ownership0.04%
Management average tenure3yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Aug 05
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Jul 30

Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Apr 21
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Sep 21
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Feb 01
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 16
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

Sep 28

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Jun 30

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

May 10
We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Jan 07
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 01
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Dan O'Connell's remuneration changed compared to Acumen Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$82m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$4mUS$598k

-US$52m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$3mUS$570k

-US$43m

Sep 30 2022n/an/a

-US$38m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$83m

Dec 31 2021US$1mUS$525k

-US$101m

Sep 30 2021n/an/a

-US$93m

Jun 30 2021n/an/a

-US$92m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$336kUS$240k

-US$7m

Compensation vs Market: Dan's total compensation ($USD3.93M) is above average for companies of similar size in the US market ($USD647.72K).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.

CEO

Dan O'Connell (54 yo)

9.9yrs

Tenure

US$3,930,011

Compensation

Mr. Daniel J. O’Connell, also known as Dan, MBA was a Key Advisor at Acidophil, LLC. He served as President until February 01, 2024 and serves as Chief Executive Officer of Acumen Pharmaceuticals, Inc. si...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel O'Connell
CEO & Director9.9yrsUS$3.93m0.042%
$ 60.1k
Matt Zuga
CFO & Chief Business Officer3.5yrsUS$1.61m0.14%
$ 196.1k
Derek Meisner
Chief Legal Officer & Corporate Secretary2.2yrsUS$1.48m0%
$ 0
James Doherty
President & Chief Development Officerless than a yearno datano data
Grant Krafft
Co-Founder28.8yrsUS$42.00kno data
Caleb Finch
Co-Founderno datano datano data
William Klein
Co-Founderno datano datano data
Russell Barton
Chief Operating Officer3.8yrsUS$223.68k0.16%
$ 228.6k
Kelly Carranza
Vice President1.3yrsno datano data
Alex Braun
VP & Head of Investor Relations2.2yrsno datano data
Robyn Moxon
Associate Director of Communications2.5yrsno datano data
Julie Bockenstette
Executive VP & Head of Human Resources3.8yrsno datano data

3.0yrs

Average Tenure

55yo

Average Age

Experienced Management: ABOS's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel O'Connell
CEO & Director18.6yrsUS$3.93m0.042%
$ 60.1k
Michael Weiner
Member of Clinical & Scientific Advisory Boardno datano datano data
Colin Masters
Member of Clinical & Scientific Advisory Boardno datano datano data
Jeffrey Cummings
Member of Clinical & Scientific Advisory Boardno datano datano data
Sean Stalfort
Independent Chairman of the Board6.1yrsUS$173.52k0.51%
$ 717.3k
Kimberlee Drapkin
Independent Director2.6yrsUS$152.27k0%
$ 0
Steven DeKosky
Member of Clinical & Scientific Advisory Boardno datano datano data
Jeffrey L. Ives
Independent Director10.5yrsUS$141.02k0%
$ 0
Reisa Sperling
Member of Clinical & Scientific Advisory Boardno datano datano data
Cynthia Lemere
Member of Clinical & Scientific Advisory Boardno datano datano data
Laura Stoppel
Independent Director4yrsUS$147.52k0%
$ 0
Stephen Salloway
Member of Clinical & Scientific Advisory Boardno datano datano data

6.1yrs

Average Tenure

64.5yo

Average Age

Experienced Board: ABOS's board of directors are considered experienced (6.1 years average tenure).